Recent years have seen notable changes in the market trends of porokeratosis, a skin disorder characterized by small raised bumps with a distinct border. In particular, there has been an increase in awareness and diagnosis of porokeratosis resulting to a growing patient population looking for medical attention. This increased awareness is due to education programs, better access to health care information, and the increasing diagnostic capabilities within most healthcare systems.
Diagnostic developments are critical in the changing porokeratosis market landscape. The use of more accurate and efficient diagnostic tools such as molecular testing and dermatopathology techniques has enabled clinicians to diagnose porokeratosis more accurately. Early detection and appropriate management are necessary for this trend to improve on patients’ outcomes as well as their quality of life.
Treatment options for porokeratosis have experienced significant breakthroughs on one side together with a move towards targeted treatments as well as minimally invasive interventions. Commonly used topical therapies include retinoids and keratolytic agents which help alleviate symptoms and support skin healing processes. In addition, laser therapy or cryotherapy may be utilized effectively in management of these lesions; hence offering less invasive alternatives when compared to traditional surgical approaches.
One major trend within the field of therapies aiming at treatment of Porokeratosis is that pharmaceutical companies are concentrating more on research and development activities. Collaborations between drug makers, universities/colleges as well as research institutions seek ways through which unmet medical needs associated with Porokeratosis can be addressed. This collation therefore helps explore novel therapeutic agents such as immune modulators and targeted biologics which could transform Porokeratosis treatment altogether.
Similarly, another noticeable development aiming at improving healthcare provision is technology integration into patient care continuum. Remote consultations, following up on patients remotely, remote monitoring can all take place via digital health solutions like telemedicine among others. Additionally given the impact made by COVID-19 pandemic, this trend is also gaining momentum as it is leading to improved access and convenience of treatment seeking for people with Porokeratosis.
Patient advocacy and support networks are playing a very crucial role in the porokeratosis market. With increased awareness, patients and their families are looking for resources, information, and emotional help. Advocacy organizations are actively sensitizing the public, they drive research initiatives and create an environment where affected persons can share experiences about porokeratosis.
Regulatory authorities also play a role in shaping the porokeratosis market. There is more favorable regulatory environment due to efforts aimed at shortening approval processes for new treatments increasing patient safety measures as well as promoting research in this area. The proactive nature of these regulatory authorities increases chances of having innovative therapies enter into the market which could be beneficial to individuals suffering from Porokeratosis.
The global porokeratosis treatment market is segmented on the basis of type of porokeratosis, diagnosis and treatment, and end-user.
By type of porokeratosis, the market is classified as Disseminated Actinic Porokeratosis (DSAP), linear porokeratosis, porokeratosis of mantoux, Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN), and punctate porokeratosis.
Based on diagnosis and treatment, the market is classified as diagnosis and treatment. The diagnosis segment is further classified as biopsy, differential diagnosis, and others. The sub-segments of differential diagnosis include squamous cell carcinoma, lichenoid keratosis, and epidermal nevus. The treatment segment is further classified as topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-Fluorouracil, immunomodulators, photodynamic therapy, retinoids, cryotherapy, lasers, immunosuppressive agents, and others. The sub-segments of immunomodulators include imiquimod and resiquimod. The sub-segments of retinoids include topical retinoids and oral retinoids. The sub-segments of immunosuppressive agents include calcineurin inhibitors and others.
By end-user, the market is classified as hospitals and clinics, diagnostic centers, drug stores, research and academic institutes, and others.
Geographically, the global porokeratosis treatment market has been segmented into America, Europe, Asia Pacific, and the Middle East and Africa. The American porokeratosis treatment market is further segmented into North America and South America. North America is further classified as the U.S. and Canada.
The European porokeratosis treatment market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and the Rest of Western Europe.
The Asia Pacific porokeratosis treatment market is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia Pacific.
The Middle Eastern and African porokeratosis treatment market is segmented into the Middle East and Africa.
The Americas dominates the porokeratosis treatment market owing to the rising prevalence of disseminated superficial actinic porokeratosis and increasing renal transplant cases, as around 10.68% of renal transplant recipients suffered from porokeratosis. According to the National Kidney Foundation, Inc., in 2014, 17,107 kidney transplants took place in the U.S. Moreover, advanced diagnostic and therapeutic solutions, high healthcare expenditure, and the presence of leading players are expected to boost the American porokeratosis treatment market.
Europe holds the second position in the porokeratosis treatment market. It is expected that the rising contribution of various marketers is likely to drive the European porokeratosis treatment market. For instance, in July 2016, Chugai and Galderma announced the global license agreement for the development and marketing of Nemolizumab worldwide. The Nemolizumab is a novel biologic for skin diseases.
Asia Pacific is the fastest growing porokeratosis treatment market owing to a huge patient pool, increasing demand for treatment, and rising healthcare expenditure. In this region, the Mibelli type is most frequent as compared to other types. In Singapore, the Mibelli type of porokeratosis was present in 56% of the porokeratosis patients in 2013, suggested by a study published in the Cases in Dermatology Journal.
The Middle East and Africa holds the lowest share of the global porokeratosis treatment market due to the presence of poor and slow developing countries, especially, in the African region.
Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on primary and secondary research.
Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the porokeratosis treatment market. It was also used to obtain key information about major players, market classification and segmentation according to industry trends, geographical markets, and developments related to the market and treatment perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases, and many others.
Global Porokeratosis Treatment Market, by Type
Global Porokeratosis Treatment Market, by Diagnosis & Treatment
Global Porokeratosis Treatment Market, by End-User
Global Porokeratosis Treatment Market, by Region
Company Profiles
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)